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Peritoneal  exudate  cells  (PECs)  play  important  roles  in  host  defense  against  Staphylococcus  aureus  and
other  pathogens.  In  this  study  we evaluated  the  potentials  of native  (pCramoll  or  Cramoll  1,4)  and  recom-
binant  (rCramoll)  lectins  from  seeds  of  Cratylia  mollis  as  immunomodulatory  tools  on  mice  PECs  infected
and  non-infected  with  S.  aureus.  Both  lectins  signiﬁcantly  enhanced  nitric  oxide,  superoxide  and  cytokines
(IL-1,  IL-6,  IFN-  and  TNF-).  pCramoll  and  rCramoll  downregulated  the  induction  of TNF-  and  IL-6
and  upregulated  the  expression  of  IL-1,  IFN-  in  S. aureus  infected  PECs.  Phagocytic  activity  of  S.  aureus
was  also  enhanced  in 27.1%  and  22.47%  by pCramoll  and  rCramoll,  respectively.  Our  results  showed  thatiotechnological tools
ectins
acrophages activation
pCramoll  induced  stronger  effects  than  rCramoll,  which  could  be  explained  by  the  different  hemaggluti-
nating  activities  of  C. mollis  isolectins  and  nature  fragmentation,  although  the  biologic  meaning  should  be
studied  in  detail  using  in vivo  models.  Future  works  will  be focused  on  the  molecular  mechanisms  involved
in  these  actions,  using  in  vitro  and  in  vivo models,  to  support  the use  of these  lectins  as biotechnological
tool in  immunological  studies.. IntroductionThe mammalian peritoneal cavity (Perc) is a sterile, ﬂuid-ﬁlled
bdominal cavity lined by a thin, translucent membrane. This
nique sterile vascular environment covers the abdominal organs,
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and it is inhabited by many interactive populations of immune
cells. These cells are collectively known as peritoneal exudate cells
(PECs), and they are typically comprised of macrophages, B1 cells
(major populations), conventional B2 cells, T cells, natural killer
cells, dendritic cells and granulocytes (mostly eosinophils) [1,2].
Diverse functions have been attributed to PECs during immune
responses. Macrophages (the major fraction of PECs), for instance,
are versatile cells that exist in almost all tissues and play crucial
roles in both the innate and adaptive immune responses. In
addition to defense, these cells play other homeostatic roles, such
as tissue remodeling during ontogenesis, the removal of senescent
and apoptotic cells from circulation, and the orchestration of many
other metabolic functions [3]. The phagocytosis of foreign partic-
ulate materials, including microorganisms, by macrophages is the
ﬁrst line of defense against microbial and intracellular parasitic
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nfections, and phagocytosis is also responsible for removing dead
ells and debris. Additionally, macrophages are highly secretory
eukocytes that represent an important source of cytokines, such
s tumor necrosis factor (TNF)- and interleukin (IL)-1, and
ytotoxic molecules, such as nitric oxide (NO) and reactive oxygen
pecies (ROS) [4,5].
As the major fraction of the lymphocyte cell population present
n the PerC, the B1 subset is distinguished from other B cell subsets
y its phenotype, developmental origin, self-renewing capacity,
nd ability to produce natural antibodies [6]. Peritoneal B1 cells
re key components in early innate immunity that participate in
he ﬁrst line of defense against infection and generate the major-
ty of natural IgM antibodies, including the antibody speciﬁc for
hosphorylcholine (PC). B1 cells also present antigens to T cells
n the spleen, inducing/triggering the adaptive immune response.
urthermore, B1 cells have a close developmental relationship with
acrophages, participating in in vitro adherent growth and F4/80
nd CD11b expression [6].
It has been reported that proinﬂammatory cytokines (includ-
ng IL-1, IL-6, IL-8, IL-12, and TNF) are secreted by immune
ells in response to infection with Staphylococcus aureus and
ther Gram-positive bacteria. However, these pathogens have
volved an abundant repertoire of mechanisms to evade the innate
mmune system [7]. S. aureus is able to release several effector
olecules to suppress or enhance cytokine production and damage
mmune cells. Although the cytokine cascade triggered by activated
acrophages and other immune cells is essential for normal host
efense, excessive or inappropriate inﬂammation can be harmful
8]. Therefore, there is a need to improve the understanding of these
ost-pathogen interactions [9].
Lectins are proteins that recognize and reversibly bind to car-
ohydrates through non-covalent interactions without altering the
tructures of their ligands [10]. Several plant lectins (such as ConA
nd PHA) have demonstrated high potential as immunomodulatory
gents [11,12]. The glucose/mannose lectin isolated from seeds of
ratylia mollis (Cramoll 1,4 or pCramoll) [13], which is a native plant
f the Brazilian Caatinga, has demonstrated remarkable biotech-
ological potential [14]. Our group has reported the expression of
unctional recombinant Cramoll 1 (rCramoll) in Escherichia coli [15].
lthough rCramoll has preserved several biophysical properties of
Cramoll, this recombinant lectin is more stable in the presence
f acidiﬁcation, high temperatures and hydrostatic pressure. These
haracteristics are related to the natural fragmentation that occurs
uring the unfolding process of pCramoll and other legume lectins
ut is absent in rCramoll [16].
Previous studies have indicated that pCramoll is an
mmunomodulatory agent able to induce Th1 and Th17 responses
17,18]. Nevertheless, these studies were restricted to spleen cells
nd did not identify whether pCramoll also exerts its effects on
ther innate immune cells, such as those present in the perit-
neal exudate. Considering the possibility that PECs, especially
acrophages, macrophages should also be involved in the in vivo
nti-parasitic and anti-tumoral responses induced by pCramoll
19,20], we aimed to investigate the immunomodulatory effects of
oth pCramoll and rCramoll on PECs. With regard to the important
ole of cytokines during bacterial infections, we also evaluated
he modulation of cytokines (IL-1, IL-6, IFN- and TNF-) in S.
ureus-infected PECs treated with pCramoll or rCramoll.
. Materials and methods.1. Lectin puriﬁcation
pCramoll was puriﬁed from C. mollis seeds using a Sephadex
-75 column (Sigma Chemical Co., USA)as previously reportedgical Macromolecules 72 (2015) 848–854 849
[13]. The E. coli Rosetta (DE3) strain was used to express rCramoll
with the expression vector pET-28a-Cramoll 1. Afﬁnity chro-
matography (Sephadex G-75 column) resulted in high pure lectin
preparations, as determined by high-performance liquid chro-
matography (HPLC), mass spectrometry and polyacrylamide gel
analyses [15,16].
2.2. Isolation of peritoneal exudate cells (PECs)
PECs were obtained from inbred strains of BALB/c mice of
both sexes at 8–10 weeks of age. Exudate cells were harvested
by peritoneal lavage using 10 mL  of ice-cold sterile phosphate-
buffered saline (PBS) (pH 7.2). After centrifugation at 120 × g for
5 min, the cell pellets were suspended in RPMI-1640 medium
supplemented with bovine calf serum (10%; v/v), penicillin and
streptomycin (100 U/mL) (all from Sigma-Aldrich). For all assays,
PECs (1 × 106 cells/mL) were cultured in 24- or 96-well plates, and
non-adherent cells were removed. All animal experiments were
performed according to the ethical standards of the Aggeu Magal-
hães Research Center (CPqAM/Fiocruz) and were approved by the
ethics committee of this institution (license number L-001/08).
2.3. Determination of nitric oxide production and cell viability
For both assays, 1 × 106 cells/mL were seeded in 96-well plates
for 24 h at 37 ◦C and 5% CO2. The cells were then treated with lectins
(0.625–10 M)  for another 24 h. Next, the supernatant was  used
for determination of NO production, and the adherent cells were
assessed by the MTT  assay. The assays were performed following
the protocols described below in quadruplicate in two  indepen-
dent experiments. The results are expressed as the mean ± standard
deviation (S.D.).
• NO production: The measurement of NO production by PECs
was determined using the Griess assay. Brieﬂy, the supernatant
(100 L) from each well was mixed with 100 L of Griess reagent
in a 96-well plate. After incubation for 15 min at room tem-
perature, the optical density was  determined at 540 nm with a
microplate reader (Benchmark Plus, Bio-Rad, CA, US). The nitrite
concentration (mol/106 cells) was  quantiﬁed by extrapolation
from a sodium nitrite standard curve for each experiment.
• MTT  assay: Cell viability was evaluated using the MTT
assay, which measures the metabolic conversion of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
salt to colored formazan dye. At the end of the incubation period,
the medium was  removed, and fresh RPMI medium containing
5 mg/mL  MTT  solution was added, and the sample was incu-
bated for 3 h. Subsequently, the medium was removed, and the
intracellular formazan product was dissolved in DMSO. The opti-
cal density (OD) was  measured at 595 nm.  Cell viability was
expressed as the % of viable cells compared to the control. LPS
(10 g/mL) was  used as a positive control of PECs activation.
2.4. Multiplex cytokine analysis
PECs (1 × 106 cells/mL) were seeded in a 96-well plate for 24 h
(at 37 ◦C and 5% CO2) and treated with lectins for an additional 24 h
(0.625–10 M).  Then, the supernatant was  used to quantify inﬂam-
matory cytokines (IL-1, IL-6, TNF- and IFN-) using Millipore
MultiScreen 96-Well Filter Plates (Bedford, MA,  USA). A multiplex
kit was  obtained from Genese Produtos Diagnósticos Ltda (São
Paulo, SP, Brazil). Assays were run according to the manufactur-
ers’ protocol. Data were collected using a Milliplex Analyzer 200
version 2.3 (Luminex, Austin, TX, USA).
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Fig. 1. Effects of pCramoll and rCramoll on PECs viability (A) and NO production.50 L.C.N.d. Silva et al. / International Journal o
.5. Mitochondrial superoxide production
Mitochondrial superoxide anion production by the PECs
itochondria was evaluated using a MitoSOXTM Red Mitochon-
rial Superoxide Indicator (Molecular Probes). PECs were treated
ith both lectins (2.5 M)  for 30 min. After trypsinization and
ashing with PBS, MitoSOXTM Reagent (1 mL/5 M)  was added to
he culture samples and incubated for 10 min  at 37 ◦C, protected
rom light. The cells were washed three times with warm PBS and
nalyzed by ﬂow cytometry (FACSCalibur-BD, San Jose, CA) using
ellQuest ProTM software (BD Biosciences, San Jose, CA) for data
cquisition and analysis (at least 10,000 events).
.6. Determination of mitochondrial membrane potential (m)
The uptake and retention of rhodamine123 (a cationic ﬂuores-
ent dye) was used to measure mitochondrial membrane potential
m). PECs (1 × 106/mL) were seeded in a 24-well plate for 24 h
at 37 ◦C and 5% CO2) and were then were treated with both lectins
2.5 M).  After 24 h of lectin treatment (at 2.5 M),  the cells was
esuspended in 1 mL  of fresh RPMI containing 2 M rhodamine123
nd incubated at 37 ◦C in a thermostatic bath for 20 min  with gentle
haking. The cells were then washed, resuspended in 1 mL  of PBS,
nd analyzed by ﬂow cytometry as described above.
.7. Phagocytosis of CFSE-stained Staphylococcus aureus
The S. aureus strain UFPEDA 02 was kindly provided by the
ntibiotics Department at the Federal University of Pernambuco
UFPEDA). Overnight S. aureus cultures were centrifuged at
0,000 × g for 10 min, washed twice with PBS, and resuspended in
he same buffer (optical density of 1.0 at 600 nm). This suspension
as incubated at 37 ◦C for 10 min  in the dark with 2.5 M of 5(-and
) carboxyﬂuorescein diacetate succinimidyl ester (CFSE, Molecu-
ar Probes, Eugene, OR) diluted in the warmed PBS. After washing
hree times with PBS to remove excess probes, the bacteria were
dded to a 24-well plate containing PECs (1 × 106 mL−1) in the pres-
nce or absence of 2.5 M lectins. The ratio of infection was 10:1
acteria/macrophages. After 2 h, adherent cells were trypsinized
nd analyzed (minimum of 10,000 events/tube) by ﬂow cytometry
see Section 2.5).
.8. Cytokine production by S. aureus-infected macrophages
PECs (1 × 106 cells/mL) were seeded in a 96-well plate for 24 h
nd infected with S. aureus at a ratio of 10:1 (bacteria/PECs) in the
resence or absence of lectins (0.625–10 M).  After 24 h, the super-
atant was assayed for inﬂammatory cytokines (IL-1, IL-6, TNF-
nd IFN-) as described above.
.9. Statistical analysis
The data were analyzed using GraphPad Prism by one-way
nalysis of variance (ANOVA) and Tukey’s test to determine
tatistical signiﬁcance. A p-value of <0.05 was considered to be
tatistically signiﬁcant. In all graphs, the bars represent the mean
alue ± S.D. The correlation indices were calculated using the
earson coefﬁcient ().
. Results
.1. Effects of pCramoll and rCramoll on cell viability and NO
roductionAs shown in Fig. 1A, the viabilities of the PECs treated with
oth lectins was similar to that of the control cells at a concentra-
ion of 0.625 M.  However, at higher concentrations, both lectins(*) Signiﬁcant differences in relation to control; (#) signiﬁcant differences between
other concentrations.
increased PECs viability compared to the control cells (p < 0.05), as
observed by the MTT  assay (Fig. 1A). Additionally, treatment of PECs
with different concentrations of pCramoll and rCramoll resulted
in a signiﬁcant production of NO (Fig. 1B). Maximum NO produc-
tion was observed in the presence of 1.25 and 2.5 M of lectins
(p > 0.05). pCramoll was able to enhance signiﬁcantly NO produc-
tion at all tested concentrations compared to the untreated cells.
The effects of rCramoll were only signiﬁcant at the 1.25 and 2.5 M
concentrations.
3.2. pCramoll and rCramoll induce the production of IL-1ˇ, IL-6,
TNF-  ˛ and IFN-
Treatment of PECs with different concentrations of pCramoll
and rCramoll resulted in a signiﬁcant enhancement in IL-1, IL-
6, TNF- and IFN- compared to the untreated cells (p > 0.05).
However, the inﬂuence of lectins on interleukin production was
not dose dependent. The most effective concentration able to
stimulate the production of all tested cytokines was 2.5 M for
both lectins. At this concentration, the IL-1 production induced
by pCramoll (148.42 ± 11.43 pg/mL) was 1.9-fold higher than
that stimulated by rCramoll (77.58 ± 3.64 pg/mL) and 3.5-fold
higher than that induced by LPS (42.41 ± 3.66 pg/mL) (p < 0.05)
(Fig. 2A). The enhancement of IL-6 production induced by
pCramoll (1495.18 ± 49.31 pg/mL) was  similar to that observed
for LPS (1531.20 ± 108.62 pg/mL) (p > 0.05). However, pCramoll
induced a 2-fold increase in the IL-6 rate compared to rCramoll
(737.58 ± 99.53 pg/mL) (Fig. 2B). Furthermore, the levels of IFN-
 in the supernatants of the cells treated with pCramoll
(121.69 ± 12.18 pg/mL) and rCramoll (77.31 ± 5.5 pg/mL) were 4.7
and 3.0- fold higher than the LPS level (26 ± 5.66 pg/mL) (p < 0.05),
respectively (Fig. 2C). pCramoll was  shown to be the most
effective inducer of TNF- production (1922.69 ± 113.29 pg/mL)
(p < 0.05), being 2.8 and 1.6-fold more potent than rCramoll
L.C.N.d. Silva et al. / International Journal of Biological Macromolecules 72 (2015) 848–854 851
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ifferences between other concentrations.
679.48 ± 26.55 pg/mL) and LPS (1214.60 ± 50.07 pg/mL), respec-
ively (Fig. 2D).
.3. pCramoll and rCramoll induced superoxide production and
oss of mitochondrial membrane potential (m)
The induction of mitochondrial superoxide by pCramoll and
Cramoll was evaluated using a MitoSOX ﬂuorescent probe. As
hown in Fig. 3, both lectins (at concentrations of 2.5 M)  enhanced
uperoxide production by the PECs. pCramoll induced an increase in
OS generation by 3.6-fold, whereas rCramoll enhanced their pro-
uction by 2.2-fold compared to the control cells. The increase in
he ROS production was corroborated by the decrease in the m
bserved in the cells treated with both lectins (Fig. 4).
.4. pCramoll and rCramoll improve S. aureus phagocytosis
After the co-culturing of treated and untreated PECs with CFSE-
abeled S. aureus,  the phagocytic activity of these cells was assayed
y ﬂow cytometry. As seen in Fig. 6, both lectins (at 2.5 M)
timulated the phagocytosis of S. aureus.  pCramoll enhanced the
hagocytic activity of the PECs by 25.38%, while it was enhanced
y 22.47% in the presence of rCramoll (Fig. 5).
.5. pCramoll and rCramoll exert immunomodulatory actions on
ECs infected with S. aureus
The infection of PECs with S. aureus induced an increase in IL-6
173.105 ± 9.15 pg/mL) and TNF- (592.39 ± 39.01 pg/mL) com-
ared to the non-infected cells. In addition, treatment with the
Cramoll and rCramoll lectins efﬁciently reduced TNF- produc-
ion by the S. aureus-infected PECs at all tested concentrations
p < 0.05) compared with the non-treated infected cells (Fig. 6A). TNF- (D) cytokines. (*) Signiﬁcant differences in relation to control; (#) signiﬁcant
At pCramroll concentrations of 1.25 M (192.96 ± 11.87 pg/mL),
2.5 M (174.96 ± 10.74 pg/mL) and 5.0 M (145.76 ± 8.97 pg/mL)
(p < 0.05), the TNF- levels decreased by 67.48%, 70.59% and
75.44%, respectively. For rCramoll, lower levels of TNF- were
achieved at 2.5 M (194.40 ± 10.55 pg/mL; 67.24%) and 5.0 M
(182.82 ± 26.60 pg/mL; 69.19%) (p < 0.05). Similarly, pCramoll and
rCramoll inhibited the release of IL-6 at all concentrations (except
in the presence of 10 M rCramoll) compared with the non-
treated infected cells (Fig. 6B). The maximum inhibitory effect was
observed at 2.5 M for pCramoll (69.22 ± 3.27 pg/mL) and rCramoll
(69.71 ± 3.30 pg/mL), demonstrating inhibitions of 60.01% and
59.7%, respectively. No signiﬁcant difference was found between
this and the other concentrations (p > 0.05).
Conversely, the lectins were able to stimulate the pro-
duction of IL-1 and IFN- at some concentrations (Fig. 6C
and D). The stimulation of IL-1 was increased signiﬁ-
cantly only when S. aureus-infected cells were treated with
pCramoll at 5 M (601.48 ± 28.29 pg/mL; 207.86%) and 10 M
(427.78 ± 164.60 pg/mg; 118.96%) and with rCramoll at 5 M
(269.05 ± 31.89 pg/mL; 37.71%). The expression of IFN- was
signiﬁcantly stimulated at all concentrations of pCramoll and at
higher concentrations of rCramoll. For both lectins, the highest
stimulation rates observed were 51.69% (11.06 ± 0.48 pg/mL)
and 31.34% (7.78 ± 0.33 pg/mL) when S. aureus-infected PECs
were co-incubated with pCramoll and rCramoll at 2.5 and 5 M,
respectively.
4. DiscussionThe PerC is a niche of important effector cells that play
pivotal roles in host defense, immune regulation, healing and
homeostasis maintenance, such as that of macrophages and B1
852 L.C.N.d. Silva et al. / International Journal of Biological Macromolecules 72 (2015) 848–854
Fig. 3. Effects of pCramoll and rCramoll on accumulation of the mitochondrial superoxide anion. (*) Signiﬁcant differences in relation to control; (#) signiﬁcant differences
between other concentrations.
Fig. 4. Effects of pCramoll and rCramoll on mitochondrial membrane potential (m). (*) Signiﬁcant differences in relation to control; (#) signiﬁcant differences between
other  concentrations.
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ells and other lymphocytes [4]. As a part of the innate immune
esponse, macrophages and B1 cells are able to rapidly recognize
athogen-associated molecular patterns (PAMPs) by pattern
ecognition receptors (PRRs), such as Toll-like receptors and
OD-like receptors. These receptors trigger signal transduction
athways, which in turn activate transcription factors that translo-
ate to the nucleus to induce the expression of large number of
enes that initiate the inﬂammatory response, e.g., interleukins,
hemokines and antimicrobial molecules. The modulation of this
mmunological response can provide broad-spectrum protection
gainst microbial pathogens, including S. aureus.  However, an
xacerbated inﬂammatory response can be harmful to mammalian
ells [8]. In this regard, there is an urgent need for the development
f novel compounds that improve and/or regulate the cellular
mmune response, which would provide novel paradigms for the
revention and/or treatment of microbial infections [9].
Despite the immunomodulatory potential of plant lectins, few
tudies have focused on their capacity to target immune effec-
or cells to combat bacterial infections. The results presented innces in relation to control; (#) signiﬁcant differences between other concentrations.
this paper indicated that pCramoll and rCramoll exert signiﬁcant
immunomodulatory effects without being toxic to PECs. Indeed, the
treatment of PECs with both lectins induced a signiﬁcant increase
in cell viability. pCramoll is well recognized as an mitogenic agent
able to enhance the proliferation of both human and murine lym-
phocytes [17,21]). Therefore, these lectins were also able to induce
the proliferation of lymphocytes and other immune cells present
in the PECs population. Moreover, this work revealed that these
lectins stimulated the PECs to produce NO. NO is synthesized via
the arginine pathway by macrophages and other immune cells,
and it has potent cytolytic actions against a range of tumors and
microorganisms [22,23].
Cytokine secretion is essential for modulation and orchestration
of a robust immune response [4]. The present study showed that
pCramoll and rCramoll enhanced IL-1, IL-6, IFN- and TNF- pro-
duction by the PECs. These cytokines are closely related to the Th1
immune response, and an increase in these effector molecules has
also been reported by our group in splenocytes treated with these
lectins [17,18]. In this regard, both pCramoll and rCramoll lectins
L.C.N.d. Silva et al. / International Journal of Biological Macromolecules 72 (2015) 848–854 853
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rig. 6. Effects of pCramoll and rCramoll on cytokine release by PECs infected with S
o  control; (#) signiﬁcant differences between other concentrations.
an be used as potential biotechnological tools to conduct immuno-
ogical studies [14]. TNF- and IL-1 are secreted by various cells,
ncluding macrophages, dendritic cells and monocytes, and they
re essential to the immunoregulatory role played by activated
acrophages. IL-1 is the most potent and pleiotropic cytokine,
hich acts by activating T helper cells and inducing the matura-
ion and clonal expansion of B lymphocytes. Similarity, TNF- is a
ey mediator of T lymphocyte and macrophage activation, exerting
ither beneﬁcial or detrimental effects on mammalian cells. It also
as an important role in the induction of inﬂammatory mediators,
uch as NO and prostaglandins. Macrophages produce high levels
f IL-6, which is a cytokine involved in the development of both the
h1 and Th2 immune responses as well as in lymphocyte prolifer-
tion and survival [24,25]. Our results showed that the treatment
f PECs with pCramoll and rCramoll induced IL-6 production. This
ncrease in IL-6 production by the PECs could have improved cell
iability and/or lymphocyte proliferation as indicated by the MTT
ssay. An increase in IFN- production was also observed in the
Cramoll- and rCramoll-treated cells. IFN-, which is mainly pro-
uced by T lymphocytes, is a pleiotropic cytokine responsible for
acrophage activation and differentiation and induction of several
roinﬂammatory genes, such as inducible NO synthase (iNOS). It
s possible that T lymphocytes present in the PECs were responsi-
le for the increase in the IFN- level in response to pCramoll and
Cramoll activation. In fact, our results showed that both lectins
ore efﬁciently induced an increase in IFN- than in LPS. The
nhancement of this cytokine may  explain the increase in TNF-
bserved in the PECs treated with both lectins because a strong cor-
elation was observed between these cytokines ( = 0.74 and 0.99s. (A) IL-1, (B) IL-6, (C) IFN- and (D) TNF-. (*) Signiﬁcant differences in relation
for pCramoll and rCramoll, respectively). TNF- is one of the earliest
genes to be induced by IFN- in macrophages [26]. Strong corre-
lations were also observed between IFN- and IL-6 ( = 0.96 and
0.97) and between TNF- and IL-6 ( = 0.83 and 0.96).
Furthermore, we found that the production of the superoxide
anion was improved by the lectin treatments, which may  have
increased the ability of the phagocytes to destroy engulfed par-
ticles. The oxidative burst is related to the generation of several
reactive species derived from oxygen (ROS) and nitrogen (RNS).
Mitochondria constantly produce ROS when oxygen and oxidative
substrates are available [27]. The superoxide anion is one of the
main ROS, and it is very cytotoxic, playing a pivotal role in defense
against infectious pathogens and tumors [28].
The phagocytosis of S. aureus by the PECs was  signiﬁcantly
improved after treatment with both lectins. In mammals, phago-
cytosis is a crucial defense mechanism that provides protection
against pathogen invasion and apoptotic cell scavenging. This pro-
cess is generally mediated by membrane receptors present on
immune cells that bind to ligands on particle surfaces, promoting
cytoskeletal and membrane remodeling necessary for their uptake
[29]. The tested lectins may  have increased the expression of these
receptors, including the Toll-like receptor 2. In fact, the expres-
sion of TLR-2 was  shown to be upregulated by ConA (seed lectin
produced by Canavalia ensiformis),  and because pCramoll (and
rCramoll) has close structural and functional similarities to ConA
[14], they may  act in similar manners. Alternatively, both lectins
may  prime these cells through intracellular signaling cascades,
leading to the improvement of phagocytic activity and induction
of proinﬂammatory cytokine production. Although macrophages,
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onocytes, and polymorphonuclear cells (professional phago-
ytes) are generally accepted as the main cellular types engaged
n the phagocytosis of foreign particles, we cannot rule out that B1
ells (present in PECs) are also involved in bacterial uptake [6].
Finally, we demonstrated the effects of pCramoll and rCramoll
n the cytokine proﬁles of PECs infected by S. aureus; the four
ytokines assessed have been strongly related to the severity of
. aureus sepsis [8]. This bacterium is considered to be the most
mportant human pathogen of the twenty-ﬁrst century due to its
xceptional capacity to acquire antibiotic resistance [7]. S. aureus
nfections are often associated with severe and prolonged host
nﬂammatory responses [30]. Proinﬂammatory cytokines (includ-
ng IL-1, IL-6 and TNF-) are secreted by macrophages in response
o S. aureus infection, playing dual roles in its pathogenicity [7,31].
mportantly, pCramoll and rCramoll downregulated the expression
f TNF- and IL-6 induced by S. aureus at all tested concentra-
ions. TNF- and IL-6 are mainly produced by macrophages and
onocytes and play important roles as mediators of fatal septic
hock induced by S. aureus [32]. However, the release of IL-1 was
nly signiﬁcantly upregulated when S. aureus-infected cells were
reated with high concentrations of both lectins. Conversely, the
xpression of IFN- in the infected cells was increased at all concen-
rations of both lectins. A strong negative correlation was  observed
etween the release of IFN- and IL-6 ( = −0.82 and −0.92) and of
FN- and TNF- ( = −0.96 and −0.64). These results corroborate
he previous study by Zhao and co-workers [33], demonstrat-
ng that IFN- regulates the levels of proinﬂammatory cytokines
uring S. aureus infection. Although IL-1 and IFN- are proinﬂam-
atory cytokines, their suppression by S. aureus has been described
s a mechanism for evading the host defense response [33–35].
lthough the molecular mechanism underlying the suppression of
L-6 and TNF- induced by lectin treatment in PECs infected with
. aureus remains to be elucidated, it is possible that decreases in
hese cytokines help to attenuate the deleterious effects of persis-
ent inﬂammatory responses at the site of infection. Furthermore,
ecause the non-infected PECs treated with both pCramoll and
Cramoll presented with cytokine proﬁles that differed from those
ound in the S. aureus-infected PECs treated with the lectins, it is
ikely that bacterial components also contribute to modulation of
he PECs response.
This paper provided the ﬁrst comparative analysis of the
mmunomodulatory actions of pCramoll and rCramoll, showing
hat native lectin differs substantially from its recombinant coun-
erpart in terms of the cytokine- and effector-induced responses. It
s important to emphasize that rCramoll is synthetized from a DNA
equence encoding mature Cramoll 1, whereas pCramoll is a combi-
ation of isoforms 1 and 4 (Cramoll 1,4). Cramoll 1 and Cramoll 1,4
howed the same immunomodulatory capacity for inducing lym-
hocyte proliferation; however, Cramoll 1,4 is able to be obtained
ith one fewer chromatographic step, and it has higher speciﬁc
emagglutinating activity than both molecular isoforms (Cramoll
 or Cramoll 4) [21]. Additionally, rCramoll is formed only by
ntact monomers, whereas other legume lectins (such as pCramoll,
ramoll 1, and commercial Con A) are composed of a mixture of
ntact and fragmented subunits [15]. These factors together can
ustify the different effects observed for pCramoll and rCramoll on
he PECs infected or not with S. aureus.  Further studies using in vivo
odels are still needed to better understand the biological meaning
f the differences existing between pCramoll and rCramoll.
In summary, the ﬁndings of this study suggest that pCramoll
nd rCramoll are able to enhance reactive species production
nd modulate the release of key proinﬂammatory cytokines by
ECs. Particularly, TNF- and IL-6 expression levels were reduced
n cells co-incubated with S. aureus,  and these cytokines are
requently associated with a striking and prolonged host inﬂam-
atory response. The results obtained in this study strongly
[
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corroborate our earlier ﬁndings of the potential use of these
lectins as biotechnological tools that may  be used to conduct fur-
ther immunological studies. Future studies will be focused on the
molecular mechanisms underlying these actions using both in vitro
and in vivo models, which may  facilitate the discovery of novel
targets for therapeutic and diagnostic applications.
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